Study of monotherapy versus combination therapy for tobacco dependence among heavily addicted smokers

详细信息    查看全文

• 作者：Sharon R. Ternullo ; ^{Ternullo@findlay.edu}Author Vitae ; Amir AbdolahiAuthor Vitae ; Geoffrey C. WilliamsAuthor Vitae
• 刊名：Journal of the American Pharmacists Association
• 出版年：2017
• 出版时间：January-February 2017
• 年：2017
• 卷：57
• 期：1
• 页码：77-81.e1
• 全文大小：223 K
• 卷排序：57

文摘

Combination therapy for tobacco dependence is becoming a standard of care. We sought to compare benefits and adverse events for combination therapy versus monotherapy for smokers in The Smokers' Health Project.MethodsThis secondary data analysis was derived from adult smokers (n = 198) who initially smoked 15 or more cigarettes per day and participated in The Smokers' Health Project. Participants were grouped as taking 1 medication or 2 concurrent medications for tobacco dependence for 1 year over the 2-year study period. Adverse events were compared between medication groups using chi-square tests. Crude and adjusted odds ratios were calculated for cessation at 6, 12, 18, and 24 months using logistic regression.ResultsNo differences were seen in the proportion of incident adverse events between the monotherapy (28.3%) and combination therapy (32.3%) groups (P = 0.54). At 6 months, the odds of quitting were less in the combination therapy group relative to those taking monotherapy (adjusted odds ratio = 0.47 [95% CI 0.24–0.93]). At 12, 18, and 24 months, the odds of quitting did not differ between therapy groups (P = 0.07, 0.33, 0.55, respectively).ConclusionMonotherapy and combination therapy for smoking cessation are similarly effective up to 24 months, and they exhibit similar adverse event attributes.